11 research firms rate Shockwave Medical at an average "Hold".

11 research firms covering Shockwave Medical (NASDAQ:SWAV) have given an average recommendation of "Hold", with a $309.11 consensus target price. Recent research reports include Needham & Company LLC's "hold" rating, Leerink Partners' downgrade to "market perform", and Canaccord Genuity Group's "hold" rating with a $335.00 target price. The company has a beta of 0.88, indicating 12% less share price volatility than the S&P 500.

May 04, 2024
4 Articles